Pharma and Biotech Daily: Roche Drops Alzheimer's Treatment, Starboard Targets Kenvue, and More Industry Updates

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Roche has ended its collaboration with UCB on Alzheimer's treatments, marking the third candidate dropped by Roche this year. Meanwhile, activist investor Starboard has set its sights on Kenvue, a division of J&J, following its $1 billion stake in Pfizer. In other news, the FDA has rejected Camurus' treatment for a rare hormonal disorder due to manufacturing issues, while Lilly is ramping up legal action against tirzepatide copycats. Trilink Biotechnologies has introduced custom sets of mRNA for screening studies, offering flexibility and expedited discovery work. Additionally, the FDA has approved Astellas' first-in-class gastric cancer treatment. Pfizer has also announced layoffs in Kansas, and Nucleus, a radiopharma-focused CDMO, is expanding with new plants. These developments reflect the dynamic landscape of the pharmaceutical industry.